Females (%)
|
81
|
77
|
71
|
Median age, years
|
49.9
|
56.5
|
50.3
|
(Q1-Q3) g
|
(30.6–58.8)
|
(48.7–63.7)
|
(40.2–60.1)
|
Ever-smoker (%)
|
230/348 (66.1)***
|
136/200 (68)***
|
254/552 (46.0)
|
HLA-DR SEb, n (%)
|
240/366 (65.6) ***
|
129/204 (63.2) ***
|
229/585 (39.1)
|
anti-CCP2 absc, % (95% CI)
|
34.9 (30.2–39.9)***
|
74.5 (68.0–80.0)***d
|
2.4 (1.4–4.0)
|
anti-CEP-1/Eno5-21 abs, % (95% CI)
|
28.9 (24.5–33.7)***
|
67.3 (60.5–73.5)***e
|
6.1 (4.4–8.4)f
|
anti-citC1359-369 abs, % (95% CI)
|
13.1 (10–17.1)***
|
32.2 (26.1–39.0)***e
|
4.4 (3.0–6.4)f
|
anti-Fibα563-583 abs, % (95% CI)
|
10.8 (8–14.4)***
|
34.2 (27.9–41.0)***e
|
5.2 (3.6–7.4)f
|
anti-Fibα580-600 abs, % (95% CI)
|
8.7 (6.2–12.1)
|
14.1 (9.9–19.7)***e
|
6.1 (4.4–8.4)f
|
anti-Fibß36-52 abs, % (95% CI)
|
29.7 (25.3–34.6)***
|
64.8 (58.0–71.1)***e
|
6.6 (4.9–9.0)f
|
anti-Fibß62-81a (72) abs, % (95% CI)
|
11.6 (8.7–15.3)***
|
14.6 (10.3–20.2)***e
|
3.1 (2.0–5.0)f
|
anti-Fibß62-81b (74) abs, % (95% CI)
|
15.9 (12.5–20.1)***
|
34.2 (27.9–41.0)***e
|
1.7 (0.9–3.2)f
|
anti-CCP-1/Fil307-324 abs, % (95% CI)
|
26.2 (22–30.9)***
|
46.2 (39.4–53.2)***e
|
3.0 (1.8–4.7)f
|
anti-Vim60-75 abs, % (95% CI)
|
13.0 (9.9–16.8)***
|
29.1 (23.3–35.8)***e
|
5.4 (3.8–7.6)f
|
anti-Vim2-17 abs, % (95% CI)
|
7.0 (4.8–10.2)*
|
11.1 (7.4–16.3)***e
|
3.8 (2.5–5.8)f
|